Clinical Trial Results:
Randomized, subject and investigator blinded, placebo-controlled
study to demonstrate the anti-inflammatory
effect of fevipiprant (QAW039) in moderate-severe asthma
patients with high sputum and blood eosinophils
Summary
|
|
EudraCT number |
2018-004381-33 |
Trial protocol |
GB FR DE ES BE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
30 Nov 2020
|
First version publication date |
30 Nov 2020
|
Other versions |
|
Summary report(s) |
CQAW039A2127_cancelled study_summary attachment |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.